PDF) Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women
Non steroidal aromatase inhibitors - Wikipedia
Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer | British Journal of Cancer
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial - The Lancet Oncology
Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin | SpringerLink
Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane - ScienceDirect
The Third-Generation Aromatase Inhibitors
The Third-Generation Aromatase Inhibitors
PDF) Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial - The Lancet
Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane - ScienceDirect
Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane - ScienceDirect
Molecules | Free Full-Text | Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target
Aromatase Inhibitors and Joint Pain: Causes and Ways of Managing - OWise UK
![PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0c397df0e388d36e159595eed864e369e42b123f/3-Figure1-1.png "PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar")
PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar
Foods To Eat & Avoid During Aromatase Inhibitor Treatment | Food for Breast Cancer
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials - The Lancet Oncology
Letrozole: Advancing Hormone Therapy in Breast Cancer - Rebecca J Lee, Anne C Armstrong, Andrew M Wardley, 2012
JCI Insight - Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
![PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0c397df0e388d36e159595eed864e369e42b123f/6-Table2-1.png "PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar")
PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar
![PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0c397df0e388d36e159595eed864e369e42b123f/5-Table1-1.png "PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar")
PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar
Femara, Arimidex and Aromasin: The Aromatase Inhibitors
Sequencing of aromatase inhibitors | British Journal of Cancer
Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1 | Nature Communications
